SHS-006(Nanjing Sanhome Pharmaceutical)

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameSHS-006(Nanjing Sanhome Pharmaceutical)

Drug Alias NameSHS-006SH-006SH006

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-T cell immunoglobulin and ITIM domainsAnti-Programmed death-ligand 1

TargetsT cell immunoglobulin and ITIM domainsProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Sanhome Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A